Safe, Standardized Cancer-Fighting Plant Extract

Health & Safety

Aveloz, a succulent plant long used in traditional medicine, contains compounds (like ingenols) that have shown promise in fighting cancer and reducing inflammation. However, its latex is highly toxic, making it difficult to safely extract these benefits. Existing methods lack standardization, pose safety risks, and produce inconsistent quality, limiting its medical use.

Core Features of the Invention

This patent outlines a controlled, standardized method for producing an Aveloz plant extract made of 50% plant sap and 50% water. The process includes sterilizing collection tools with UV light, harvesting during specific morning hours to ensure potency, refrigerating at -5°C, and carefully packaging the product. The final extract contains key active compounds such as Ingenols A–H, Eufol, and PKC.

Inventive Step

The novelty lies in combining precise harvesting conditions, sterilization techniques, and exact dilution ratios to create a safe, reproducible extract that retains the therapeutic compounds while reducing toxicity risks. This process allows for pharmaceutical-grade production that can meet regulatory standards—something lacking in previous extraction methods.

Tangible Benefits

  • Safety & Consistency: Reduces the danger of toxic exposure while ensuring uniform potency.
  • Versatility: Can be formulated into capsules, ointments, or solutions for various treatments.
  • Cost-Effectiveness: Efficient production can lower costs, making it more widely accessible.
  • Therapeutic Potential: Laboratory tests in mice showed up to an 80% reduction in tumor weight within 21 days.

Broader Impact

If proven safe and effective in humans, this invention could contribute to cancer treatment options, anti-inflammatory therapies, and pain relief. Its standardized approach could set a precedent for processing other medicinal plants with toxic components. Additionally, sustainable cultivation practices promote environmental protection while supporting the growth of plant-based medicine as a regulated, credible alternative in healthcare.

Disclaimer

The image and video are AI-generated based on the description of the invention in its patent application and are intended for illustrative purposes only.

It explains the concept and is not the actual product as it still needs to be developed.

Market need

  • Oncology demand is huge: Global oncology drugs are a ~$200–221B market in 2024, projected to ~$518–668B by 2032–2034. Even niche penetration can be meaningful.
  • Herbal/botanical interest is rising: Estimates for global herbal medicine range widely ($87B–$233B in 2024), reflecting varied definitions but clear momentum. A regulated, standardized botanical addressing serious disease is differentiated within this space.

Technical feasibility

  • The invention’s process control (UV sterilization, timed harvesting, defined 50:50 sap–water dilution, cold-chain handling) addresses the core problem with Aveloz: toxicity and batch variability.
  • Risk flag: A closely related compound, ingenol mebutate (Picato), was withdrawn in the EU over increased skin-cancer risk, underscoring the need for robust human safety/efficacy data before commercialization.
  • Regulatory path: In the U.S., true medical claims require the FDA botanical drug route (IND → Phase trials → NDA). Only a handful of botanical drugs have ever been approved, so the bar is high but defined.

Potential applications

  • Primary: Oncology (adjunct or specific indications) if clinical data ultimately support efficacy/safety.
  • Secondary: Dermatology (e.g., warts), anti-inflammatory/analgesic topicals, and possibly veterinary health—likely as separate programs with tailored formulations and risk–benefit profiles.
  • Non-Rx nutraceutical: Only feasible with non-disease claims and careful positioning; otherwise it risks enforcement.

Uniqueness

  • What’s novel: A standardized, reproducible extraction and composition addressing toxicity, purity, and consistency—historically the blockers for Aveloz. This is more a process/IP moat than a new molecular entity.
  • Competitive set: Crowded herbal/nutraceutical field, but few entrants pursue full drug-grade, trial-backed botanicals.

Market sizing (directional)

  • Total addressable (drug path): oncology TAM in the hundreds of billions; even a 0.1% share implies ~$200–600M potential at today’s market size.
  • Alternative (herbal/OTC): large but lower-price, with intense competition and limited claims ($87B–$233B+ in 2024).

Overall commercial viability (bottom line)

  • Upside: If Phase 2/3 trials demonstrate clear benefit with acceptable safety, the drug route could unlock substantial value, leveraging oncology’s scale and the differentiation of a standardized botanical.
  • Key risks: Safety concerns linked to ingenol class, the cost/timeline of full drug development, and the small historical success rate of botanical NDAs.
  • My take: Promising but high-risk/high-reward—commercially attractive only with rigorous clinical proof and early regulator engagement. As a lower-risk bridge, consider non-disease topical applications with strong quality controls while advancing the core oncology program under an IND. Also invest in CMC standardization and IP around the process to protect margins.
  • Go/No-Go: Proceed to pre-IND consultation and targeted tox and MoA work; pause broad consumer commercialization until safety is unambiguously established.